Repligen gets positive results on improved pancreatic MRI
Repligen Corp. (Nasdaq: RGEN) today reported positive results from a Phase 3 study of RG1068, a synthetic human secretin designed to improve magnetic resonance imaging of the pancreas.
The Phase 3 study was intended to evaluate the safety and efficacy of RG1068 in imaging for patients with pancreatic disease using endoscopy as a diagnostic reference. According to the Waltham company, the study showed statistically significant improvement in sensitivity of detection of abnormalities with minimal loss of specificity. Three radiologists were involved in the trial and reported “highly significant” improvements in image quality and confidence in diagnostic findings when compared with MRI alone, according to Repligen.